Treatment of tardive dyskinesia. 3. Clinical efficacy of a dopamine competing agent, methyldopa.
D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000209:etiology; D012559:Schizophrenia / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000009:adverse effects
D014149:Tranquilizing Agents; D008750:Methyldopa